| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | - | - | 0 | 15.236 | 44.646 | 46.858 | 49.047 | 66.228 | 64.156 |
| Total Income - EUR | 0 | - | - | 0 | 15.236 | 44.735 | 46.882 | 49.049 | 66.257 | 64.213 |
| Total Expenses - EUR | 128 | - | - | 1.790 | 19.183 | 36.948 | 38.777 | 62.240 | 59.827 | 62.906 |
| Gross Profit/Loss - EUR | -128 | - | - | -1.790 | -3.948 | 7.788 | 8.104 | -13.192 | 6.429 | 1.307 |
| Net Profit/Loss - EUR | -128 | - | - | -1.790 | -4.380 | 6.480 | 6.698 | -14.675 | 5.401 | 1.072 |
| Employees | 0 | - | - | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Pipera Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 335 | - | - | 1.002 | 844 | 692 | 544 | 413 | 301 | 299 |
| Current Assets | 21.865 | - | - | 20.939 | 25.781 | 32.397 | 40.837 | 22.826 | 27.788 | 18.458 |
| Inventories | 16.832 | - | - | 17.830 | 19.627 | 21.650 | 28.421 | 13.192 | 16.975 | 9.609 |
| Receivables | 3.489 | - | - | 3.068 | 5.144 | 6.098 | 6.907 | 5.016 | 7.922 | 3.472 |
| Cash | 1.544 | - | - | 41 | 1.010 | 4.649 | 5.509 | 4.619 | 2.891 | 5.377 |
| Shareholders Funds | -32.536 | - | - | -32.869 | -36.612 | -29.438 | -22.087 | -36.831 | -31.318 | -30.072 |
| Social Capital | 45 | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 54.736 | - | - | 54.810 | 63.237 | 62.528 | 63.468 | 60.070 | 59.407 | 48.830 |
| Income in Advance | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Pipera Pharma S.r.l.